SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July, 2018
Commission File Number: 001-38480
(Name of registrant)
1344 Summer Street, Suite 412 Halifax, Nova Scotia B3H 0A8, Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
[ ] Form 20-F [ X ] Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: July 25, 2018||By:||/s/ Pierre Labbé|
|Name: Pierre Labbé|
|Title: Chief Financial Officer|
Form 6-K Exhibit Index
|99.1||News Release dated July 25, 2018 announcing company's presentation at the Canaccord Genuity conference on August 8, 2019.|
FOR IMMEDIATE RELEASE
IMV Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference
Halifax, Nova Scotia; July 25, 2018 – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that IMV Chief Executive Officer Frederic Ors will present a corporate update at the Canaccord Genuity 38th Annual Growth Conference, which takes place August 8-9, 2018, in Boston, MA.
IMV’s presentation details include:
Date: Wednesday, August 8, 2018
Time: 10:30 – 10:55 a.m. ET
Location: Melbourne Room at the Intercontinental Hotel, Boston, MA
There will be a live webcast of IMV’s presentation accessible at http://wsw.com/webcast/canaccord30/imv/. The webcast will be archived for 90 days following the live presentation. A copy of the presentation will be available on the Events & Presentations page of IMV’s website: www.imv-inc.com.
IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at www.imv-inc.com.
Contacts for IMV:
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: email@example.com
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: firstname.lastname@example.org
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: email@example.com